Here’s Who Just Picked Up Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) reported that Svlsf V, Llc. has picked up 2,579,490 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 2,579,490 representing a 26.6% stake in the company.
For those not familiar with the company, KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
A glance at Kalvista Pharmaceuticals Inc. (NASDAQ:KALV)’s key stats reveals a current market capitalization of 70.68 million based on 9.93 million shares outstanding and a price at last close of $7.16 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-04-14, Cha picked up 7,364 at a purchase price of $5.00. This brings their total holding to 4,204,562 as of the date of the filing.
On the sell side, the most recent transaction saw Renzi unload 10,000 shares at a sale price of $3.70. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Why Earth Science Tech Inc (OTCMKTS:ETST) Shares Rose Nearly 30%
Earth Science Tech Inc (OTCMKTS:ETST) shares were up 27.78% to $1.38 on Monday to $1.38 and flat in after-hours trading. Share prices have been trading in a 52-week range of $0.18 to $1.70. The company has a market cap of $55.85 million at 40.47 million shares outstanding.
Earth Science Tech Inc is a biotechnology company that is focused on nutraceuticals and bioceuticals for use in various industries, such as health, wellness, nutritional supplements, cosmetic and alternative medicine to manage illnesses and the quality of life for consumers around the world. It sells its products through its retail store located in Coral Gables, Florida, and through the Internet.
The company is also focused on delivering nutritional and dietary supplements that help with treating symptoms, such as chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea and aging. This may include products, such as vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products. These products will be in various formulations and delivery forms, including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs.
In a press release this week, Earth Science Tech Inc announced that itsnew wholly owned subsidiary, Cannabis Therapeutics, Inc. will be releasing new Cannabinoid-based Drugs and Nutraceuticals. In particular, Cannabis Therapeutics will begin by inventing & launching 2 new cannabinoid-based pharmaceutical drugs and 3 new advanced cannabinoid-based nutraceutical products using Earth Science Tech’s existing Cannabis CBD Patent, IP, invention, technology and future technology.
“I am very enthusiastic about Cannabis Therapeutics position in the cannabis industry to become a leader in cannabinoid research and development. Our imminent new developments and efforts have the potential to expedite our numerous upcoming cannabis cannabinoid-based therapeutic products to help aid people with certain conditions and disorders worldwide, in the later part of 2017. We are focused on cannabinoid-based therapeutic drugs, functional foods and nutraceuticals (retail consumer markets worldwide). We look to announce later this week a New Scientific Advisory Board which will include myself, Dr. Michel Aube, as the Chairman of the Advisory board to Cannabis Therapeutics, Inc. as well as other World Class Scientists,” said Dr. Michael Aube, CEO of Earth Science Tech Inc.
Cannabis Therapeutics plans on distinguishing itself from many competing cannabinoid-focused biotechnology companies with its competent capital apportionment. Its board of directors and upcoming new scientific advisory board intends to broaden the current operations of the Cannabis Therapeutics to include a variety of other products, solutions, laboratories and expertise. Its goal is to discover solutions for conditions for which there is presently no effective treatment as well as other medical disorders with the application of known and novel cannabis cannabinoid-based products.
ETST is extremely fortunate to have attracted world leaders to our executive leadership team and Board of Advisors. All of them are contributing their passion, time and expertise to the development of Cannabis Therapeutics unique cannabinoid-based products and solutions. Cannabis Therapeutics goal is to help advance the cannabis-cannabinoid healthcare industry and have a positive impact on the wellbeing of humans worldwide” Dr. Aube continued.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.